In PARK2 KO mice treated with bleomycin (BLM), Pirfenidone reversed enhanced lung fibrosis and oxidative alterations, verifying its anti-fibrotic effects and highlighting its potential as a therapeutic option for IPF (129). The gene discussed is PRKN; the disease is idiopathic interstitial pneumonia.